Award Number: W81XWH-11-1-0061

TITLE: Role of Autophagy in Keratin Homeostasis in Breast Cancer

PRINCIPAL INVESTIGATOR: Sameera Kongara

CONTRACTING ORGANIZATION:
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
Piscataway, NJ 08854-5627

REPORT DATE: March 2014

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Role of Autophagy in Keratin Homeostasis in Breast Cancer**

**Abstract**

Autophagy is an evolutionarily conserved catabolic process where the proteins and organelles of a cell are degraded using the lysosome. Defective autophagy has been implicated in mammary tumorigenesis as autophagy deficient Beclin1+/- mice develop mammary hyperplasias at a higher frequency than their wild-type counterparts and Beclin1 is monoallelically deleted in 40% of human breast tumors. Phospho(S73)-K8, a modification required for keratin filament reorganization under stress, in autophagy-deficient cell lines, and mouse mammary tissues. We conclude that interfering with the phosphorylation of K8 at this residue however, does not alter the reorganization of the keratin network under stress and therefore, are unable to investigate the role of this phosphorylation site in the context of autophagy deficiency. On the other hand, using gene expression analysis, we have identified increased Keratin 6 expression in autophagy-deficient cell lines, tumors generated from these cell lines and mouse mammary gland tissues. We are currently attempting to understand the association between of Keratin 6 expression and autophagy-deficiency in mammary tumorigenesis.
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>6</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>14</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>16</td>
</tr>
<tr>
<td>Conclusion</td>
<td>17</td>
</tr>
<tr>
<td>References</td>
<td>19</td>
</tr>
<tr>
<td>Supporting Data</td>
<td>22</td>
</tr>
</tbody>
</table>
Introduction:

Autophagy is an evolutionarily conserved process involving the targeting of cytoplasmic proteins and organelles to the lysosome via a double-membrane vesicle called the autophagosome. Defective autophagy has been implicated in mammary tumorigenesis as the essential autophagy gene, Beclin1, is mono-allelically deleted in ~50% of breast tumors and Beclin1+/− mice develop mammary hyperplasias. The increased tumorigenesis of autophagy-deficient cells is attributable to their propensity towards genomic instability. Our more recent work demonstrated that autophagy-deficient mammary cells have increased levels of ER and oxidative stress as well as abnormal keratin reorganization. Importantly, we identified increased levels of Phospho(S73)-K8, a modification that has previously been implicated in the reorganization of keratins, are associated with low Beclin1 levels in immortalized mouse mammary epithelial cells, tumors derived from these cells, and in native mouse mammary glands. Furthermore, high levels of Phospho(S73)-K8 were associated with low Beclin1 levels in human breast tumors, indicating that Phospho(S73)-K8 could potentially function as a marker for defective autophagy. In an attempt to generate a robust autophagy-deficiency signature that relied on a panel of proteins instead of a single marker, Phospho(S73)-K8, we began investigating potential differences in post-translational modifications on Keratin 8 and other members of the keratin family (as these are known to be heavily modified under stress) between autophagy-competent and deficient immortalized mammary epithelial cells; however, we were unable to detect any post-translationally modified keratin species that was unique to autophagy-deficient cells. Next, we investigated if interfering with Keratin 8 phosphorylation at Ser73 had a functional consequence on autophagy-competent and deficient cells with respect to their ability to survive under stress, and found no significant differences between the two cell lines. Therefore, phosphorylation of Keratin 8 at Ser73 appears to not have a significant effect on keratin network reorganization or the ability of cells to survive under stress. Next, we employed microarray analysis to investigate the differences between autophagy-competent and deficient cells and their ability to form tumors. One of the most highly upregulated genes in apoptosis-competent and disabled Beclin1+/− cells was Keratin 6; in tumors derived from Bcl-2 overexpressing Beclin1+/− cells, the degree of upregulation was even higher, indicating that high Keratin 6 expression might be a driver of tumorigenesis in an autophagy-deficient background. We are currently in the process of investigating the relationship between Keratin 6 and autophagy-deficiency and how it may play a role in driving tumorigenesis mediated by insufficient autophagy. Understanding the underlying mechanisms that are responsible for defective-autophagy driven tumorigenesis will aid in the development of successful treatment strategies of autophagy-competent and defective tumors.
Specific Aim 1: Identify the post-translational modifications, such as phosphorylation, glycosylation and ubiquitination, of keratin 8 and its obligate partner keratin 18 under normal, metabolic stress and recovery conditions in iMMECs in vitro.

Task 1: Identify post-translational modifications of keratins 8 and 18 in autophagy-competent (Beclin1\(^{+/+}\) and Atg 7\(^{+/+}\)) and autophagy-deficient (Beclin1\(^{+/-}\) and Atg 7\(^{-/-}\)) immortalized mouse mammary epithelial cells (iMMECs) under normal, metabolic stress (glucose and oxygen deprivation) and recovery conditions using mass spectrometry

Results:

Year 1

We first looked at the levels of keratin 8 and phopho(S73)-keratin 8 in apoptosis-inhibited Beclin1\(^{+/+}\) and Beclin1\(^{+/-}\) iMMECs overexpressing Bcl-2 under normal and metabolic stress (no glucose, low oxygen conditions mimicking the tumor microenvironment) conditions. Keratin 8 levels are modestly higher in the Beclin1\(^{+/-}\) cells compared to their wild-type counterparts (Figure 1A). The amount of phospho(S73)-keratin 8 in both Beclin1\(^{+/+}\) and Beclin1\(^{+/-}\) decreases with an increase in metabolic stress, and the protein levels increase during recovery (Figure 1A, D5+1dr), when cells are subjected to oxidative stress as normal oxygen and nutrient conditions are restored. The expression of phospho(S73)-keratin 8 has previously been reported as a marker of mitosis (Liao et al., 1997), apoptosis (Liao et al., 1997) and stress due to heat (Liao et al., 1997) and stimulation with Fas ligand (He et al., 2002). However, the expression of phospho(S73)-keratin 8 decreases in wild-type cells (by immunoblotting, Figure 1 and by immunofluorescence (Kongara et al., 2010)), while a conflicting picture emerges in Beclin1\(^{+/-}\) cells, with decreases detected by immunoblotting (Figure 1), and increases detected by immunofluorescence (Kongara et al., 2010).

Since phosphorylation of keratins is thought to play an important role in their solubility (Toivola et al., 2002), we examined the levels of K8 and phospho(S73)-K8 in the Triton-x soluble fraction and the insoluble fractions of protein extracts from Beclin1\(^{+/+}\) and Beclin1\(^{+/-}\) cells with Bcl-2. The level of K8, when examined by immunoblotting the high salt extract fraction, appears to be steady in the wild-type cells while more protein is detected upon the induction of stress in the heterozygous cells (Figure 1B, 1. K8). The level of keratin 8 does in fact, increase with metabolic stress since the protein from the cells metabolically stressed over days was collected in a fixed volume of lysis buffer, and there is a loss if viability of cells upon the induction of metabolic stress (Karantza-Wadsworth et al., 2007). Therefore, the presence of similar levels of protein from fewer cells indicates that the fraction of insoluble K8 increases in both the wild-type and heterozygous cells upon metabolic stress. Similarly, a Coomassie stained blot containing the insoluble proteins (equal volume lysate loaded from equal volume gels) detects equal amounts of K8 across the timepoints in the wild-type cells, and an increase in protein levels in the heterozygous cells (Figure 1D). Due to a loss of
viability of cells upon the induction of stress, the levels of insoluble keratin 8 increase in both the Beclin1+/+ and Beclin1+/- cells overexpressing Bcl-2, given that the number of cells and protein concentration of equal volume lysates decreases over the stress period. Furthermore, the bands detected in the Coomassie gel are common to both Beclin1+/+ and Beclin1+/- cells, with no unique band (migrating differences due to post-translational modifications such as phosphorylation or glycosylation) detected (Figure 1D). In the soluble fraction, K8 levels appear to be stable across the timepoints examined in both the Beclin1+/+ and Beclin1+/- cells (Figure 1C). In the case of the soluble fraction, equal protein was loaded on the basis of the BCA-RAC protein quantitation assay; however, there is no direct means to verify equal loading. Proteins such as actin that are commonly used to verify loading in whole cell extracts are present in both the soluble and the insoluble fractions, thereby rendering them ineffective as controls for loading purposes.

Phospho(S73)-K8 is undetectable in the soluble fraction (Figure 1C), and levels of the protein in the insoluble fraction remain the same with upon metabolic stress, and increase slightly during recovery in the wild-type cells, while there appears to be a decrease in the levels of protein in the Beclin1+/- cells upon induction of stress, and an increase during recovery (Figure 1B). However, there remains the difficulty of verifying the loading levels of protein, which has remained a persistent issue in our present pursuit. In general, a Coomassie stained gel containing the insoluble fraction is used as a loading control for immunoblotting various proteins from this fraction, while the cell number is normalized to study the protein levels in the soluble fraction. These controls are untenable in our case since we are interested in the differences between Beclin1+/+ and Beclin1+/- cell lines as well as the differential effects of metabolic stress within each cell line. From the results presented thus far and our previous data (Kongara et al., 2010), it is evident that the levels of keratin 8 change upon the induction of stress and to different degrees between the wild-type and Beclin1+/- cells, and therefore, the Coomassie stained gel would not be an ideal control to study proteins of the insoluble fraction by western blotting. Similarly, normalizing cell number as a means to control for loading for studying the proteins in the soluble fraction is not ideal for our purposes of comparing between autophagy-competent and impaired cell lines, since autophagy is critical for protein turnover, and could directly affect overall protein content and therefore, levels of protein. Problems with controlling protein loading also make performing an immunoprecipitation of keratins challenging, since keratins are fairly insoluble proteins, and the detergents that have a higher efficiency solubilizing keratins such as Empigen BB successfully dissolve only around 50% of the total keratin pool (Ku et al., 2004), and therefore, quantifying any observed differences between autophagy-competent and deficient cells can be arduous.

Phosphorylation of Keratin 8 at Serine-73 has previously been reported to be important for keratin filament reorganization (Ku et al., 2002). Upon treatment with okadaic acid, a majority NIH-3T3 cells transfected with K8 S73A (point mutation at position 73, resulting in an alanine substitution for a serine residue) construct had intact filaments while cells with WT K8 and K8 S73D (a phosphorylation mimicking construct) had significant reorganization; no difference in filament organization was observed using all three constructs under regular growth conditions (Ku et al, 2002). Since
phosphorylation of keratin 8 is modulated under stress (Ku et al., 2002), and Beclin1+/+ and Beclin1+/− cells behave differentially under stress (Karantza-Wadsworth et al., 2007, Kongara et al., 2010), we examined whether the differences manifest between cells of the two genotypes were modulated by Keratin 8 phosphorylation at serine 73. Towards this end, we stably transfected iMMECs of both genotypes with WT K8, K8 S73A and K8 S73D constructs, and examined the effects of metabolic stress upon viability and filament reorganization using clones expressing comparable levels of protein (Figure 2A). In both Beclin1+/+ and Beclin1+/− cells, the S73D mutant survived better than the S73A or the WT construct (Figure 2B). However, there were no discernable differences in the filament organization upon the induction of stress in cells overexpressing WT K8, K8 S73A or K8 S73D, irrespective of the genotype (TROMA-1/K8 staining, Figure 3). While the levels of Phospho(S73)-K8 increase more in the Beclin1+/− cells compared to the Beclin1+/+ cells upon the induction of stress, consistent with previous results (Kongara et al., 2010), there was no observable difference between the WT K8, K8 S73A and K8 S73D within each genotype (Figure 4), indicating that the overexpression of wild-type or mutant constructs does not interfere with phosphorylation (Figure 4) or reorganization of the keratin network (Figure 3). Furthermore, we tested whether two parental clones of Beclin1+/+ and Beclin1+/− cells overexpressing WT K8, K8 S73A and K8 S73D would differ in their ability to handle stress caused by treatment with Hanks buffered salt solution (HBSS), which results in amino acid deprivation. Our viability assays in HBSS do not result in the emergence of a consistent trend among the two Beclin1+/+ and Beclin1+/− clones, with the K8 S73A overexpressing cell line being the best survivor in one wild-type parental (Clone 1), while the WT K8 survives best in the other parental cell line of the same genotype (Clone 2); in the Beclin1+/+ cells, the S73D mutant survives best in the parental Clone 1 while it does poorly in the Clone 2 (Figure 5). Hence, there is clonal variability, and no consistent trend emerges. Taken together, phosphorylation of Keratin 8 at serine 73 does not appear to be important for the survival differences observed in Beclin1+/+ and Beclin1+/− cells under stress (Figure 2B and 5), or keratin filament reorganization under stress (Figure 3 and 4).

Recently, we analyzed Beclin1+/+ and Beclin1+/− iMMECs with and without the overexpression of Bcl-2 as well as tumors generated from orthotopic implantation of Bcl-2 overexpressing iMMECs in immuno-compromised mice, by using gene expression profiling. One of the most upregulated genes in autophagy compromised cells and tumors in our study was keratin 6, which was expressed over 8-fold and 10-fold in Beclin1+/− iMMECs without and with Bcl-2 respectively, compared to their wild-type counterparts (Figure 6). Tumors generated from autophagy-compromised iMMECs overexpressing Bcl-2 exhibited an even greater upregulation of keratin 6 with Beclin1+/−, Bcl-2 tumors expressing over 35-fold higher levels of keratin 6 mRNA compared to their wild-type counterparts (Figure 6). Furthermore, we examined mammary glands from both virgin and multiparous, 11 month old Beclin1+/+ and Beclin1+/− mice, and observed the presence of distinct Keratin 6 cells in Beclin1+/− glands irrespective of the pregnancy status, while the wild-type gland had few Keratin 6 positive cells (Figure 7). In the developing and proliferating mammary glands from 4.5-week old mice, Keratin 6 expression is higher in Beclin1+/+ tissue compared to Beclin1+/− tissue (Figure 8). Although the precise function of Keratin 6 is unknown, it is sporadically expressed in the
terminal end buds of developing mammary glands (Smith et al., 1990, Sapino et al., 1993), and has more recently been reported as a marker of bipotent progenitor cells (Bu et al., 2011). Mice that develop mammary tumors due to the presence of transgenic Wnt1 or other downstream components of this pathway, including β-catenin and c-myc, have an increased population of K6 cells (Li et al., 2003). Additionally, in the skin, Keratin 6 expression is necessary for a rapid wound healing response (Wojcik et al., 2000). Given that Keratin 6 expression is associated with autophagy-deficiency, we are interested in understanding the basis for this association and if Keratin 6 expression is linked to the tumor initiating potential of autophagy-impaired cells. Towards this end, we will be generating Beclin1+/+ and Beclin1+-/- iMMECs overexpressing Bcl-2 with a stable knockdown of Keratin 6, and examining their ability to tolerate metabolic stress as well as their tumor forming capabilities.

### Year 2

#### Results:

We obtained a set of GFP-tagged short hairpin RNAs targeting K6 and transiently expressed the vectors in Beclin1+/+ and Beclin1+-/- iMMECs overexpressing Bcl-2 to determine which hairpins were most efficient in reducing the levels of Keratin 6. As shown if Figure 9, shRNA #2 and shRNA #3 were most the most effective in knocking down K6 levels. Next, we generated stable clones of Beclin1+/+ and Beclin1+-/- iMMECs that expressed the GFP-tagged K6 shRNA (#2 and #3) or a non-targeting/luciferase-targeting vector as controls. Upon the examination of these clones, we observed that some Beclin1+-/- clones expressing the control hairpins had little to no K6 protein (Figure 10). This result indicated that the K6 expression within the Beclin1+-/- cell line might be variable. Therefore, we examined the levels of Keratin 6 by immunofluorescence in Beclin1+/+ and Beclin1+-/- cells. As shown in Figure 11, consistent with our gene expression analysis results, Beclin1+/+ cells express more K6 than Beclin1+-/- cells; however, the expression is heterogenous as only a some cells in a given population are K6. Next, we examined tumors derived from Beclin1+/+ and Beclin1+-/- overexpressing Bcl-2 iMMECs for their K6 expression and observed that while autophagy-deficient tumors had higher levels of K6, only a subset of cells within the tumor expressed K6 (Figure 12). Furthermore, examination of human breast cancer cell lines HCC1937 and HCC1954, which have low Beclin1 levels in a panel of human breast cancer cell lines, also revealed the presence of a few distinct K6 positive cells (Figure 13). Finally, K6 expression has been reported to be both constitutive and inducible in the skin, although there are currently no reports on whether its expression in the mammary gland is constitutive or inducible. Taken together, these observations indicate that knocking down the expression of an inducible protein such as K6 is not a feasible task.

Since K6 expression is most evident in developing mammary and we observe differences in K6 expression of Beclin1+/+ and Beclin1+-/- glands, we examined whole mounts of mammary glands from 6.5-week old Beclin1+/+ and Beclin1+-/- mice to look for differences in post-natal mammary gland development. As shown in Figure 14,
mammary glands from Beclin1+/− mice exhibited increased side-branching and more ductal filling compared to Beclin1+/+ mice. The mammary gland is a unique organ in the fact that most of its development occurs post-natally. At birth, the mammary epithelium consists of a rudimentary ductal structure that is confined to the nipple area, which during puberty, elongates and branches to occupy the fat pad of the mammary gland. Subsequent estrus cycles regulate side-branching, which refers to the outgrowth of small epithelial structures from the primary ducts. Pregnancy increases side-branching and promotes the formation of alveoli, which are the structures responsible for the production of milk. Upon the weaning of pups, involution commences where the mammary gland reverts to its pre-pregnant state (Brisken and O’Malley, 2010).

Pubertal mouse mammary gland development, which begins at 3 weeks and continues up to 8 weeks of age, is regulated by the confluence of systemic hormones including estrogen, progesterone and prolactin and local growth factors such as Insulin growth factor-1 (IGF-1), Hepatocyte growth factor (HGF), and Fibroblast growth factor (FGF) (Parmar and Cunha, 2004, Stingl, 2011). Estrogen initiates pubertal ductal outgrowth and branching, while progesterone influences the side branching of the duct during the estrus cycle in a paracrine manner via the progesterone receptor (PR), RANKL and Wnt4 (Stingl, 2011). It is thought that under the influence of estrogen, ER+ epithelial cells release the membrane protein Amphiregulin in a manner dependent upon its cleavage by the protease ADAM17 (Brisken and O’Malley, 2010). Following its release, Amphiregulin binds to EGFR present in the stroma. Additional factors released by the stroma that are yet to be identified are believed to cause the proliferation of the epithelial cells (Brisken and O’Malley, 2010). Thus, extensive crosstalk between the epithelium and the stroma via paracrine signaling is responsible for the proliferation and normal development of the mammary gland. In keeping with the theme of paracrine signaling in normal mammary gland development, PR+ cells secrete RANKL upon the induction of progesterone. This secreted RANKL elicits a proliferative response in PR− cells via the action of Wnt4 although the precise details of this process are unknown (Brisken and O’Malley, 2010).

To test if increased PR and RANKL signaling is responsible for the increased side branching observed, we stained mammary gland tissues from 5 and 6.5-week old Beclin1+/+ and Beclin1+/− mice for these proteins together with the proliferation marker, Ki67. Indeed, higher levels of Ki67, PR and RANKL signaling are observed in the Beclin1+/− glands (Figures 15-17), indicating that the increased proliferation observed in Beclin1+/− glands maybe due to increased PR and RANKL signaling. Recent work from other laboratories has demonstrated that MMTV-RANKL transgenic mice have extensive side-branching and develop hyperplasia but not tumors in the mammary gland, in a manner strikingly similar to Beclin1+/− mice (Fernandez-Valdivia et al., 2009). Importantly, RANKL mice have been reported to be susceptible to 7,12-dimethylbenz[a]anthracene (DMBA)-induced carcinogenesis in the presence of progesterones (Gonzalez-Suarez et al., 2010). Furthermore, it has been demonstrated that the mammary stem cell compartment expansion in response to progesterone is mediated by RANKL, and the absence of RANKL delays hormone-induced tumorigenesis (Schramek et al., 2010). Since we detect increased side-branching, PR and RANKL
signaling, we hypothesize that the tumorigenic potential of $\text{Beclin1}^{+/\text{c}}$ mice is mediated by RANKL and its associated signaling pathway, thereby increasing the susceptibility of these mice to DMBA-induced tumorigenesis. We are currently in the process of testing this hypothesis.

**Year 3:**

**Results:**

The mammary gland provides a unique experimental system due to the fact that most of its development occurs during puberty which begins at 3 weeks of age in mice. At this time, the undeveloped mammary rudiment present in a mouse can be dissected out and a portion of another mammary gland from a donor mouse can be transplanted into this recipient mouse, which allows the full reconstitution of a functional mammary gland of the donor’s genotype in the recipient mouse (Medina et al., 2010; Visvader and Smith, 2011). The ability to transplant mammary glands is attributed to the presence of stem cells in the mammary gland, and can be recapitulated by simply injecting stem cells (Visvader and Smith, 2011).

Since K6 expression is detected in bipotent progenitor cells of the mammary gland (Bu et al., 2011), and we observe increased K6 expression in $\text{Beclin1}^{+/\text{c}}$ glands, we isolated mammary stem cell containing populations of mammary epithelial cells from $\text{Beclin1}^{+/\text{c}}$ and $\text{Beclin1}^{+/\text{c}}$ mice, and transplanted them contralaterally into the cleared fat pad of wild-type mice. Using this assay, we examined glands generated from transplanted cells of $\text{Beclin1}^{+/\text{c}}$ and $\text{Beclin1}^{+/\text{c}}$ genotype for levels of K6, which were elevated in the $\text{Beclin1}^{+/\text{c}}$ native mammary glands. As shown in Figure 18, we observed higher levels of K6 in the $\text{Beclin1}^{+/\text{c}}$ transplanted glands compared to wild-type glands, indicating that the transplantation model accurately reflects the scenario occurring in the native mammary glands. To further validate our findings, we examined the levels of PR and RANKL, two proteins implicated in mammary gland development that are present at higher levels in $\text{Beclin1}^{+/\text{c}}$ native mammary glands. As shown in Figure 19 and 20, we detected a higher level of both these proteins in the transplanted $\text{Beclin1}^{+/\text{c}}$ glands. Notably, these findings underscore a cell-autonomous role for $\text{Beclin1}^{+/\text{c}}$ mammary epithelial cells in mediating increased K6, PR and RANKL expression since the stroma and the levels of circulating hormones are similar due to the contralateral transplantation of $\text{Beclin1}^{+/\text{c}}$ and $\text{Beclin1}^{+/\text{c}}$ cells.

In the mammary gland, PR signaling has been reported to induce the expression of RANKL. In immune cells and fibroblasts, cytokines such as TNF-$\alpha$ and IL-1$\beta$ drive RANKL expression (Braun and Zwerina, 2011). To test whether these cytokines can play a role in RANKL signaling in the mammary gland, we stained $\text{Beclin1}^{+/\text{c}}$ and $\text{Beclin1}^{+/\text{c}}$ transplant outgrowths for TNF-$\alpha$ and IL-1$\beta$. As shown in Figure 21, higher levels of these cytokines were observed in autophagy-deficient transplants, indicating that in addition to PR signaling, cytokines can drive RANKL signaling in the mammary gland during development.
Autophagy-defective macrophages have been demonstrated to have aberrant cytokine secretion due to increased inflammasome activity. Inflammasomes are protein complexes that function to process pro-caspase-1 into its active form (Martinon et al., 2009). Following activation, caspase-1 in turn processes cytokines such as IL-1β and IL-18, leading to their maturation and secretion. Importantly, the NLRP3 inflammasome, which is present in immune cells, is activated in response to a wide variety of stimuli including ROS and impaired phagocytosis (Martinon et al., 2009, Gross et al., 2011). Additionally, autophagy-impaired (Atg7−/−, Atg16L−/−, LC3−/− and Beclin1+/−) macrophages secrete high levels of IL-1β and IL-18 due to increased inflammasome activity; this increased activity is triggered by the high levels of ROS detected in autophagy-defective macrophages (Saitoh et al., 2008, Nakahira et al., 2011, Zhou et al., 2011). To test whether increased levels of ROS mediate the increase in cytokines in the mammary gland, we examined the expression of 8-O-dG (8-Hydroxyguanosine), a marker of oxidative stress, in Beclin1+/+ and Beclin1+/− transplant outgrowths. As shown in Figure 22, higher levels of 8-oxo-dG were detected in Beclin1+/− transplant outgrowths. Thus, increased ROS levels in Beclin1+/− glands may drive the increased expression of cytokines, which in turn may lead to increased RANKL expression resulting in enhanced proliferation and tumorigenesis.

Overexpression of RANKL makes mice more susceptible to the chemical carcinogen, DMBA (Gonzalez-Suarez et al., 2010). To test whether increased RANKL expression observed in the Beclin1+/− mammary glands is responsible for mediating the increased tumorigenicity associated with these glands, we administered the carcinogen, DMBA, to Beclin1+/+ and Beclin1+/− mice. Preliminary results from a small cohort are depicted in Figure 23, and do not reveal significant differences between the two genotypes, although firm conclusions can be arrived at only upon the completion of the experiment.

Specific Aim 3: Determine beclin1 levels, expression of other essential autophagy regulators, such as LC3, atg5 and atg7, and levels of post-translationally modified keratins 8 and 18 and their interactors in human breast cancer specimens to identify potential autophagy functional status signatures in breast cancer.

Task 1: Human breast cancer tumor microarrays will be obtained from Yale Cancer Center Tissue Microarray Facility (in collaboration with Dr. Bruce Haffty, CINJ) and stained using immunohistochemistry for autophagy regulators such as beclin1, LC3, atg5 and atg7 together with keratins 8, 18 and their post-translational modifications identified in Aim1, as well as proteins found to be important for keratin remodeling in Aim2. Staining patterns will be scored by two independent investigators, and will hopefully result in the generation of signatures for the functional status of autophagy in breast tumors. (1 year)

Results:

Year 1:
In collaboration with Dr. Bruce Haffty, we stained a tumor microarray containing 516 tissue specimens from patients whose medical history including hormone receptor and metastases status was known with antibodies recognizing the Phospho(S73)-K8 epitope, and scored them based on a scale from 0 to 3 where 0 corresponds to little to no staining, while 3 denotes very high levels of protein expression. Statistical analysis in collaboration with Dr. Dirk Moore, revealed the association of high levels Phospho(S73)-K8 with low levels of distant metastasis (p<0.05). Additionally, we stained another TMA obtained from NCI that had accompanying patient case history with the same antibody, and scored them on a scale of 0 to 4, with 0 representing the detection of no protein and 4 the highest levels. As shown in Figure 24, 41.8%, 60.9% and 49% of invasive node negative, node positive and distant metastases samples respectively, stained for no Phospho(S73)-K8 (0 staining), while few samples of normal breast tissue (24.3) and normal breast-fibroadenoma (28.2%) demonstrated this phenomenon. Since high Beclin1 levels correlate with low Phospho(S73)-K8 levels (Kongara et al., 2010), which in turn appears to correlate with invasive potential, we are interested in pursuing if autophagy status impacts progression to metastases.

**Year 2:**

We are in the process of staining a tumor microarray to correlate the levels of Keratin 6 with autophagy deficiency status, by staining it for the levels of Beclin1.
Key Research Accomplishments:

Year 1:

- Identifying the association between low levels of Phospho(S73)-K8 with high levels of distant metastasis.
- Identifying increased K6 (a marker of bipotent progenitor cells) mRNA levels in autophagy-deficient cell lines, tumors generated from these cell lines and mouse mammary gland tissues compared to their wild-type counterparts.
- Identifying that overexpression of WT and mutant keratin constructs does not disrupt the keratin network in Beclin1+/+ and Beclin1+/- iMMECs under conditions of metabolic stress; additionally, overexpression of WT or mutant keratin constructs does not impact viability of Beclin1+/+ and Beclin1+/- cells under conditions of metabolic stress or amino acid deprivation.

Year 2:

- Identifying increased K6 protein expression in autophagy-deficient immortalized mouse mammary epithelial cells and in tumors derived from these cells. The K6 protein however, was expressed only in a subset of cells.
- Identifying increased side-branching, ductal filling and proliferatin in Beclin1+/- mammary glands.
- Identifying increased PR and RANKL signaling as the probable mechanism responsible for the increased proliferation and accelerated development observed in Beclin1+/- mammary glands.
- Identifying the presence of increased amounts of cytokines such as IL-1β and TNF-α in developing Beclin1+/- mammary glands, which could partly be responsible for the phenotype observed in these glands.

Year 3:

- Identifying increased K6 protein expression in autophagy-deficient transplanted mammary outgrowths.
- Identifying increased PR and RANKL signaling in autophagy-deficient transplanted mammary outgrowths compared to contralateral wild-type outgrowths, indicating that the mammary epithelial cells, and not the stroma or hormones, drive increased PR and RANKL signaling.
- Identifying the presence of increased amounts of cytokines such as IL-1β and TNF-α in Beclin1+/- transplanted mammary outgrowths, which could partly be responsible for the phenotype observed in these glands.
- Identifying increased levels of 8-oxo-dG, a marker of oxidative stress, in Beclin1+/- mammary transplant outgrowths, indicating that higher levels of ROS
may drive increased production of cytokines, which in turn may result in elevated RANKL signaling to mediate tumorigenesis.
Reportable Outcomes:

Year 1:

*Beclin1*+/+, Bcl-2 and *Beclin1*+/−, Bcl-2 immortalized mouse mammary epithelial cell lines stably overexpressing human WT K8, K8 S73A and K8 S73D constructs were generated for the purpose of this study.

Year 2:

A review article titled “The interplay between autophagy and ROS in tumorigenesis” was published in Frontiers Oncology with the help of this grant support.

Year 3:

Two manuscripts, titled “Monoallelic Becn1 loss deregulates the mammary cell hierarchy and promotes parity-associated and WNT1-driven mammary tumorigenesis” and “The context dependent role of autophagy in haploinsufficient p53 driven mammary tumorigenesis”, are currently under preparation, and were supported by this award.

Co-presented the poster “Expansion of immature mammary epithelial populations promotes Wnt1-driven mammary tumorigenesis in an autophagy-deficient mouse model” at the AACR Advances in Breast Cancer Research Conference in San Diego, CA (October 3-6, 2013).

The recipient of this award was awarded a PhD.
Conclusions:

Year 1:

We were unable to make a valid conclusion from our examination of the differences in soluble and insoluble keratin fractions of Beclin1+/+ and Beclin1+/- cell lines overexpressing Bcl-2 since usual methods of normalization are not useful in our case. Typically, the insoluble fraction is normalized by examining the keratin levels; however, we are interested in comparing the keratin levels and therefore, this is not a good control for our purposes. Additionally, the soluble fraction is generally normalized to the cell number, which again is not helpful in our case, since alterations in the levels of autophagy impact the overall protein level of the cells and therefore, autophagy-competent and deficient cells might have varying levels of overall protein.

Overexpression of WT K8, K8 S73A and K8 S73D constructs does not disrupt the keratin network or affect the levels of Phospho(S73)-K8 in Beclin1+/+ and Beclin1+/- cell lines, overexpressing Bcl-2. Additionally, this overexpression does not affect viability under conditions of metabolic stress or amino acid deprivation. However, high levels of Phospho(S73)-K8 is associated with low levels of distant metastasis from Tumor Microarray staining. We are investigating if autophagy status of tumors affects their metastatic potential, since low beclin1 levels correlate with high Phospho(S73)-K8 levels, which in turn correlate with low levels of distant metastases.

High mRNA expression of K6, a marker of bipotent progenitor cells and a protein whose expression is associated with a wound healing response in injured cells, was detected in Beclin1+/- cell lines, allograft tumors generated from these cell lines as well as mammary gland tissue of Beclin1+/- mice, compared to their wild-type counterparts. We are currently testing if K6 expression is responsible for the higher tumorigenic potential of autophagy-deficient cell lines, when compared to the autophagy-competent ones. Identifying the proteins responsible for the tumorigenecity of autophagy-compromised cell lines will enable the development of drugs that target these proteins and will aid in the treatment of a particular subset of human breast tumors.

Year 2:

We were unable to knockdown the levels of K6 in Beclin1+/+ and Beclin1+/- iMMECs overexpressing Bcl-2 since its expression is sporadic in a given population of cells. Moreover, the fact that K6 expression can be both constitutive and inducible depending upon external stimuli/stress (for example, wounding) makes this task challenging.

Since K6 expression is highest during pubertal mammary gland development, we examined whole mounts of mammary glands from Beclin1+/+ and Beclin1+/-, which revealed that the autophagy-deficient glands had increased side-branching and ductal filling. As signaling via progesterone receptor (PR) is responsible for side-branching in
the mammary gland, we examined the levels of PR in mammary glands from \textit{Beclin1}^{+/+} and \textit{Beclin1}^{+/−} mice. We observed higher levels of PR and the proliferative marker Ki67, in \textit{Beclin1}^{+/−} glands indicating that these glands had higher levels of proliferation possibly due to increased PR signaling compared to wild-type glands. Furthermore, we observed higher levels of RANKL, which functions downstream of PR in mediating the proliferative effects of progesterone, in \textit{Beclin1}^{+/−} mammary glands. We are currently in the process of investigating whether the increased levels of PR and RANKL signaling observed in the \textit{Beclin1}^{+/−} glands are responsible for the increased hyperplasia observed in \textit{Beclin1}^{+/−} glands by treating \textit{Beclin1}^{+/+} and \textit{Beclin1}^{+/−} mice with the carcinogen, DMBA.

**Year 3:**

We took advantage of the ability stem cells within a mammary epithelial cell population to reconstitute a functional mammary gland upon transplantation to examine the role of autophagy-deficiency in mammary gland development and tumorigenesis. Our study revealed that \textit{Beclin1}^{+/−} mammary transplant outgrowths exhibited increased K6 expression, which was associated with increased nuclear PR and RANKL levels, indicating that the \textit{Beclin1}^{+/−} transplanted outgrowths activate the same pathways as the native mammary gland. More importantly, these findings reveal that the increased PR and RANKL signaling observed in association with the \textit{Beclin1}^{+/−} genotype is due to the inherent nature of the mammary epithelial cells since contralaterally transplanted wild-type cells, which are under the influence of the same stroma and hormones, do not exhibit the activation of these pathways.

Activated PR increases RANKL expression in the mammary gland, although cytokines such as TNF-\(\alpha\) and IL-1\(\beta\) are reported to induce RANKL in immune cells and fibroblasts. Since aberrant cytokine expression is commonly associated with autophagy-deficiency, we examined the levels of these cytokines in \textit{Beclin1}^{+/+} and \textit{Beclin1}^{+/−} transplant outgrowths and observed higher levels of these proteins in the autophagy-deficient background. Thus, increased cytokines in \textit{Beclin1}^{+/−} glands may result in increased RANKL expression. Increased levels of ROS are reported to cause the increased expression of cytokines in autophagy-deficient cells, and therefore, we examined oxidative stress levels in \textit{Beclin1}^{+/+} and \textit{Beclin1}^{+/−} transplant outgrowths using the marker, 8-O-dG (8-Hydroxyguanosine); we observed higher levels of this marker in \textit{Beclin1}^{+/−} transplant outgrowths. Thus, higher ROS levels in \textit{Beclin1}^{+/−} glands may result in increased cytokine production, which in turn may drive increased RANKL expression to mediate mammary cell proliferation and increase tumorigenesis.
References:


20
Supporting data:

A. Whole cell lysates

<table>
<thead>
<tr>
<th>Days of metabolic stress</th>
<th>Beclin1+/+, Bcl-2</th>
<th>Beclin1+/−, Bcl-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phospho(S73)-K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. Insoluble fraction

<table>
<thead>
<tr>
<th>Days of metabolic stress</th>
<th>Beclin1+/+, Bcl-2</th>
<th>Beclin1+/−, Bcl-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phospho(S73)-K8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Soluble fraction

<table>
<thead>
<tr>
<th>Days of metabolic stress</th>
<th>Beclin1+/+, Bcl-2</th>
<th>Beclin1+/−, Bcl-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phospho(S73)-K8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. Coomassie stained insoluble fraction

<table>
<thead>
<tr>
<th>Days of metabolic stress</th>
<th>beclin1+/+, Bcl-2</th>
<th>beclin1+/−, Bcl-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>K8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K18</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Figure 1:**

1A - Total cell lysates of Beclin1+/+ and Beclin1+- cells overexpressing Bcl-2 were subjected to metabolic stress (no glucose, low oxygen conditions) for 5 days and allowed to recover (normal nutrient and oxygen conditions) for 1 day and probed with antibodies recognizing K8 and Phospho(S73)-K8.

1B – Lysates of insoluble protein fractions isolated from Beclin1+/+ and Beclin1+- cells overexpressing Bcl-2 and metabolically stressed for 4 days and allowed to recover for 1 day were probed for levels of K8 and Phospho(S73)-K8. For the K8 blot (1. K8) highlighted in yellow, **20 µl of equal volume** lysates was loaded, and for the K8 blot (2. K8) highlighted in turquoise, **equal amount of protein** was loaded on the basis of the BCA-RAC assay. The BCA-RAC assay was used to load equal amount of protein for the the Phospho(S73)-K8 blot.

1C – Lysates containing the triton-x soluble proteins were isolated from metabolically stressed (4 days, and 1 day recovery) Beclin1+/+ and Beclin1+- cells with Bcl-2 and probed for K8 and Phospho(S73)-K8 levels. Equal amounts of protein were loaded on the basis of the BCA-RAC assay. No Phospho(S73)-K8 was detected in the soluble fraction; the lane highlighted in red contains the lysate of the insoluble fraction of Beclin1+/+, Bcl-2 cell line, which serves as a positive control.

1D – Equal volume of lysates containing the insoluble protein component of metabolically stressed Beclin1+/+ and Beclin1+- cells were loaded onto a gel and stained with Coomassie Blue to detect keratins, which are the predominant components of insoluble extract.
Figure 2:

2A – Western blot showing the overexpression of human WT K8, K8 S73A, and K8 S73D constructs in two Beclin1+/+, Bcl-2 and Beclin1+/-, Bcl-2 parental cell lines. The antibody used is specific to the human protein and does not detect any mouse protein (absence of band in the first lane, which contains the parental Beclin1+/+, Clone 2 lysate).

2B - Viability of Beclin1+/+, Bcl-2 and Beclin1+/-, Bcl-2 cells overexpressing WT K8 (blue line), K8 S73A (pink line) and K8 S73D (yellow line) constructs metabolic stress (no glucose, low oxygen conditions) for a duration of 0, 1, 2, 3, and 4 days (D0, D1, D2, D3, D4) and allowed to recover (restoration of normal glucose and oxygen conditions) for a day (D4+1Dr). Using cell lines derived from a single parental clone
of each genotype, it appears that the K8 S73D construct aids in the survival of both Beclin1+/+ and Beclin1+/− cells overexpressing Bcl-2 under stress.
Figure 3: TROMA-1 (K8) expression and filament organization in Beclin1+/+, Bcl-2 and Beclin1+/-, Bcl-2 cells overexpressing WT K8, K8 S73A and K8 S73D constructs treated with metabolic stress for a period of 0, 1, 2, 3 and 4 days (D0, D1, D2, D3 and D4, respectively) and allowed to recover for a day (D4+1Dr). The heterozygous cells express higher levels of the protein compared to the wild-type cells in response to stress (day 3, 4 and during recovery); however, no differences in expression or filament structure are seen across the WT and mutant keratin constructs within and between each genotype. (Note: The slide containing the day 4 timepoint of the Beclin1+/-, Bcl-2 overexpressing WT K8 was damaged and could therefore, not be imaged.)
**Figure 4:** Phospho(S73)-K8 expression in *Beclin1+/+, Bcl-2* and *Beclin1+/−, Bcl-2* cells overexpressing WT K8, K8 S73A and K8 S73D constructs treated with metabolic stress for a period of 0, 1, 2, 3 and 4 days (D0, D1, D2, D3 and D4, respectively) and allowed to recover for a day (D4+1Dr). The heterozygous cells express higher levels of the protein compared to the wild-type cells on day 2, 3 and 4, and during recovery; however, no differences in expression are seen across the WT and mutant keratin constructs within and between each genotype.
**Figure 5:** Viability of Beclin1\(^{+/+}\), Bcl-2 and Beclin1\(^{+/-}\), Bcl-2 cells overexpressing WT K8 (blue line), K8 S73A (pink line) and K8 S73D (yellow line) constructs (derived from two parental clones, Clone 1 and 2) under amino acid deprivation (Hanks buffered salt solution treatment) over a period of 5 days. No consistent pattern emerged from this assay.
Figure 6: Gene expression profiling of Beclin1+/+ and Beclin1+- immortalized mouse mammary epithelial cells (iMMECs) with and without Bcl-2 and tumors generated from iMMECs with Bcl-2 indicates the presence of a higher Keratin 6 mRNA levels in the autophagy-deficient background compared to their wild-type counterparts.
Figure 7: Mammary gland tissue from 11-month old Beclin1+/+ and Beclin1+/- tissue was stained for Keratin 6 (in green) and DAPI (in blue). The Beclin1+/- tissues express higher levels of Keratin 6 irrespective of the number of pregnancy cycles of the gland.
**Figure 8:** Mammary gland tissue from 4.5-week old *Beclin1*+/+ and *Beclin1*+/− mice demonstrates higher levels of Keratin 6 in the autophagy-compromised tissue compared to the autophagy competent one.
**Figure 9:** Beclin1+/+ and Beclin1+/- iMMECs overexpressing Bcl-2 were transiently transfected with various shRNA constructs targeting K6 (shK6 #1 - #5) or a non-targeting vector control (sh vector) to test the efficacy of knockdown. The K6 blot above shows that sh K6 constructs #2 and #3 had the best knockdown. These constructs were used to conduct subsequent studies.
Figure 10: shRNA constructs targeting K6 (shK6 #2 and #3) or a non-targeting vector control (sh vector) were introduced into Beclin1+/+ and Beclin1+/- iMMECs overexpressing Bcl-2 by lentiviral infection. Following infection, resistant colonies were allowed to emerge and independent colonies were picked. The blot here contains lysates of Beclin1+/+, Bcl-2 cells that stably expressed the vector control (sh vec, Clone #1-#5) or shRNA targeting K6 (sh K6, 1-6). Unexpectedly, we observed a heterogeneous expression of K6 in the vector controls. Clones #1-3 have no detectable levels of K6, while Clones #4 and #5 have robust K6 expression. This result indicated not all cells within the parental Beclin1+/+, Bcl-2 cell line express K6.
Beclin1\textsuperscript{+/+} iMMECs

Beclin1\textsuperscript{+/-} iMMECs

**Figure 11:** Immunofluorescence on Beclin1\textsuperscript{+/+} and Beclin1\textsuperscript{+/-} iMMECs revealed that while Beclin1\textsuperscript{+/-} cells did indeed have higher levels of K6 expression, not all cells within a cell line demonstrated K6 positivity.
**Figure 12:** Tumors generated from orthotopic implantation of Beclin1+/+;Bcl-2 and Beclin1+/-;Bcl-2 iMMECs demonstrate higher levels of Keratin 6 in the autophagy-compromised background compared to the autophagy competent one.
**Figure 13:** Human breast cancer cell lines HCC1937 and HCC1954, which have low beclin1 mRNA levels relative to a panel of human breast cancer cell lines, were stained for K6 by immunofluorescence. Similar to the iMMECs, the human breast cancer cell lines express K6 sporadically.
**Figure 14:** Whole mounts prepared from the native mammary glands of 6.5-week old Beclin1+/+ and Beclin1+/− mice show increased side-branching and ductal filling in Beclin1+/− mice.
Figure 15: Mammary glands from 5-week old Beclin1+/mice exhibit increased levels of the proliferation marker, Ki67.
Figure 16: Mammary glands from 5-week old Beclin1+/+ mice exhibit increased levels of K6 and progesterone receptor (PR).
Figure 17: Mammary glands from 6.5-week old Beclin1+/− mice exhibit increased expression of RANKL.
Figure 18: Beclin1+/- mammary transplant outgrowths exhibit a higher level of K6 expression compared to outgrowths derived from Beclin1+/+ cells.
Figure 19: Beclin1+/− mammary transplant outgrowths exhibit a higher level of PR expression compared to outgrowths derived from Beclin1+/+ cells.
**Figure 20:** Beclin1+/− mammary transplant outgrowths exhibit a higher level of RANKL expression compared to outgrowths derived from Beclin1+/+ cells.
**Figure 21:** Beclin1+/− mammary transplant outgrowths exhibit a higher expression level of the cytokines TNF-α and IL-1β compared to outgrowths derived from Beclin1+/+ cells.
Figure 22: Beclin1+/− mammary transplant outgrowths exhibit a higher expression level of the oxidative stress marker, 8-O-dG (8-Hydroxyguanosine) compared to outgrowths derived from Beclin1+/+ cells.
Figure 23: Preliminary mammary tumor free survival curves of \textit{Beclin1}^{+/+} and \textit{Beclin1}^{+-} mice treated with DMBA. Although these curves do not detect a difference yet, the experiment will provide conclusive results upon completion.
**Figure 24:** Human breast tumor microarray containing tissue from normal breast, DCIS, normal breast-fibroadenoma, and breast tumor samples from patients with invasive disease (node negative, positive and distant metastasis) was stained with a Phospho(S73)-K8 antibody. Low levels (0-1 score) of Phospho(S73)-K8 are present mostly in invasive specimens (node negative 41.8%, node positive 60.9%, and distant metastasis 49%), while this phenomenon is not observed in the normal tissue (24.3% in normal, and 28.2% in normal breast-fibroadenoma), indicating that autophagy status might be an important determiner of the metastatic potential of cells.